Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenagamtide in Obesity (AMAZE 9)
NCT07720271Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 3 trial of amycretin in obesity, sponsored by Novo Nordisk. Started Aug 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07720271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720271.